List of Antibodies Companies in Missouri - 7

Antibody Research Corporation is a biotechnology company that specializes in offering custom antibody and protein services including monoclonal and polyclonal antibody development, gene cloning, in vitro antibody production, cell line engineering, and assay development.

OUR COMPANY BioMed Valley Discoveries, Inc., is a clinical stage biotechnology company with a mission to address unmet patient needs across a wide spectrum of diseases. Operating since 2007, BioMed Valley Discoveries advances its mission with commercial capabilities and resources typically unavailable to academic institutions. As a member of the Stowers Group of Companies, our stable long-term funding allows us to advance programs that may not fit within the model of more traditional clinical development groups. OUR APPROACH BioMed Valley Discoveries leverage several hundred experts at leading academic and clinical institutions to move projects forward in the early stages of clinical development. Our partners have a proven track record of scientific rigor and experience in efficient study execution. Our selection of development partners is based on our desire to address unmet patient needs and achieve critical development milestones as swiftly as possible. Through this approach, we endeavor to quickly answer scientific questions and determine next steps in the development process. OUR TEAM BioMed Valley Discoveries calls on the talents of a core leadership team of scientists who are focused, passionate, and committed to advancing new medical innovations to improve the lives of patients with difficult-to-treat diseases. Our team brings extensive experience from pharma, biotech, and academia. By utilizing unique advantages from each of these settings, BioMed Valley Discoveries creates a highly creative and functional drug development environment. We take a nimble and thoughtful approach to advancing programs with a focused sense of urgency, allowing for the most efficient path forward.

Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.

For scientists in life sciences discovery, and biopharmaceutical and diagnostics segments utilizing antibodies, biologically active proteins, and assays, reproducible science is the key to unlocking the scientific doors. Leinco Technologies Inc. adheres to ISO 9001:2015 and ISO 13485:2016 quality standards, and provides access to antibodies and proteins used in a broad range of life sciences applications uncovering interactions in cancer, infectious diseases and immunology. Our proprietary techniques result in the highest purity antibodies (monoclonal, recombinant and polyclonal) and proteins enabling scientists globally to generate reproducible science and faster time to scientific results across a broad range of cell, tissue and in vivo applications (e.g. spatial biology, flow cytometry, pre-clinical in vivo and in vitro studies). For our many partners, the Leinco scientists with over 30 years’ experience take a consultative approach and are committed to delivering the highest quality CDMO services (e.g. antibody scale-up and purification, optimized conjugation to reporter molecules and assay development/manufacturing) that save time and ensure our customers are successful in their programs.

Likarda is a biotech company developing enabling technologies to transform the way cell therapies are delivered and optimized. Our revolutionary method to coat cells with stealth hydrogels, called Core Shell Spherification® (CSS), protects cells from destruction, keeping them viable while maintaining them in the intended location within the body. Unlike our competitors, Likarda has developed a library of over 50 different hydrogel formulations that work with Core Shell Spherification®, resulting in the ability to uniquely tailor the coating molecules to the specific requirements of the therapeutic cells themselves. From durable and long-term coatings to degradable coatings that deliver cells over days, weeks, or months, we can create exclusive hydrogel formulations tailored for each therapeutic application. Likarda is the remarkable culmination of visionary leadership, science that is just as artistic as academic, and a compelling urge to do what’s right. As we move forward, we have well-defined, long-range goals with added opportunities for flexibility and growth.

Mayflower Bioscience is an experienced, specialist life science distributor in the USA. Headquartered in St. Louis, we identify and commercialize unique products for biological research, drug discovery and bioproduction for emerging life science companies. Areas of product focus include Regenerative and Degenerative Medicine, Biomarkers, Cell Biology and Molecular Biology.

At Mediomics, we strive to help scientists and researchers discover new drugs. We are an innovative life sciences company specializing in homogeneous assay kits. Our goal is to make the lives of scientists and researchers easier. Our focus is quick and easy assay kits, high affinity binding reagents, and biosensors for detecting biologically and therapeutically important macromolecules, biomarkers, and pathogens. These kits are valuable resources for scientists in the pharmaceutical, biopharmaceutical, and biotechnology industries, as well as university, hospital, and national laboratory researchers. Our platform Bridge-It, FRET-PINCER, and TRF-PINCER technologies have already been adapted for the detection of a range of important macromolecules, including cAMP, tryptophan, S-adenosyl methionine, PDE, biotin, insulin, C-peptide, albumin, C-reactive protein (hCRP), IgG, IgM, E. coli, and others.